News

AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial
AAVB-039 delivers the full-length ABCA4 -protein, addressing the root cause of the disease and enabling treatment of all patients, independent of mutationCELESTE is informed by the STELLA prospective ...
IPPMEDIA9d
‘Mosquito control strategies not suitable for dengue surveillance‘
VECTOR control strategies in fighting malaria and dengue fever must be adapted to mosquito species’ outdoor feeding behaviour ...